Sign in

CIK 0001422143

  • Non-accelerated filer
  • Smaller reporting company

Kura Oncology, Inc.

Sign in to watch
Ticker
KURA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
611547851
Phone
+1 858-500-8800
Business address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
Former names
ZETA ACQUISITION CORP III
  1. 4 Open-market sale Chief Scientific Officer sold 23,726 shares at $9.78 ($231,931)
  2. 4 Open-market sale Director sold 10,000 shares at $10.98 ($109,764)
  3. 4 Planned sale Chief Legal Officer sold 8,804 shares at $11.18 ($98,401)
  4. 4 Grant or award President and CEO acquired 182,500 shares (grant or award)
  5. 4 Open-market sale Chief Commercial Officer sold 8,887 shares at $11.18 ($99,329)
  6. 4 Open-market sale Chief Medical Officer sold 15,485 shares at $11.18 ($173,074)
  7. 4 Open-market sale SVP, Finance & Accounting sold 4,539 shares at $11.18 ($50,732)
  8. 4 Planned sale Chief Operating Officer sold 6,902 shares at $11.18 ($77,143)
  9. 4 Open-market sale Chief Commercial Officer sold 8,891 shares at $8.94 ($79,505)
  10. 4 Planned sale Chief Legal Officer sold 8,805 shares at $8.94 ($78,736)
  11. 4 Planned sale Chief Operating Officer sold 6,892 shares at $8.94 ($61,630)
  12. 4 Open-market sale Chief Medical Officer sold 12,314 shares at $8.94 ($110,114)
  13. 4 Open-market sale President and CEO sold 36,615 shares at $8.94 ($327,419)
  14. 4 Open-market sale SVP, Finance & Accounting sold 4,541 shares at $8.94 ($40,607)
  15. 4 Open-market buy President & CEO bought 50,000 shares at $8.20 ($410,145)
  16. 4 Open-market buy President and CEO bought 50,000 shares at an average $6.06 ($303,201)
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 3 of 14 · 276 filings